FDA Expands Use for Insulin Aspart Injection Pumps
Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.
Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps. This expansion will improve glycemic control in adults with type 1 or type 2 diabetes.
The insulin aspart injection pumps were approved by the FDA in 2017 for use by intravenous infusion under supervision by a health care professional or by a subcutaneous multiple daily injection (MDI) in adults with diabetes.
The pumps are the only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. They are administered at the beginning of a meal or within 20 minutes after starting a meal.
The approved label expansion was based on data from onset 5. The study investigated the efficacy and safety of continuous subcutaneous insulin infusion of insulin aspart injection pumps compared to insulin aspart (NovoLog) in adults with type 1 diabetes.
Insulin aspart injection pumps should be used in accordance with the insulin pump’s instructions for use. The pumps are available in multiple dosing options, including:
- 10 mL vial for use in insulin pumps or MDI
- 3 mL FlexTouch® for MDI
- 3 mL PenFill® Cartridge for NovoPen Echo for MDI
- Features of a Rapid-Acting Insulin Option for Adult Patients With Diabetes
- Approvals Sought for Use of Fast-Acting Insulin Aspart in Children
FDA approves Fiasp for use in insulin infusion pumps for adults with type 1 or type 2 diabetes [news release]. Plainsboro, NJ; PR Newswire; October 22, 2019. https://prnmedia.prnewswire.com/news-releases/fda-approves-fiasp-for-use-in-insulin-infusion-pumps-for-adults-with-type-1-or-type-2-diabetes-300942998.html. Accessed October 22, 2019.